Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab induction therapy in TNF antagonist-failure Crohn's disease
NL-OMON38117Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical response at Week 6. Started Aug 2012; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON38117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38117.